Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients1). In patients with an elevated BMI, a 5-10% reduction in weight has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia.2 Diet, exercise, and behavior modification are the traditional methods for losing weight, but they are often inadequate; the American College of Cardiology no longer recommends that all patients try lifestyle modification alone...
- Comparison Table: Some Drugs for Weight Management (online only)
- Intravesical Mitomycin (Zusduri) for Bladder Cancer (online only)
- Taletrectinib (Ibtrozi) — Another Kinase Inhibitor for Non-Small Cell Lung Cancer (NSCLC) (online only)
- Telisotuzumab Vedotin (Emrelis) for Non-Small Cell Lung Cancer (online only)
- Berdazimer Gel (Zelsuvmi) for Molluscum Contagiosum
- Upadacitinib (Rinvoq) for Giant Cell Arteritis
- Teal Wand — An At-Home Cervical Cancer Screening Device
- Onapgo — An Apomorphine Subcutaneous Infusion for Parkinson's Disease
- In Brief: Low-Dose Chlorthalidone (HemiClor) for Hypertension
- COVID-19 Update: Full Approval for Novavax COVID-19 Vaccine
- COVID-19 Update: mRNA COVID-19 Vaccines and Myocarditis
- COVID-19 Update: mNEXSPIKE — A New Moderna mRNA Vaccine for COVID-19
- Addendum: Drugs for Chronic Heart Failure
- Avmapki Fakzynja Co-Pack for Ovarian Cancer (online only)
- Penpulimab (Anniko) for Nasopharyngeal Carcinoma (online only)
- Prademagene Zamikeracel (Zevaskyn) for Recessive Dystrophic Epidermolysis Bullosa (online only)
- Retifanlimab (Zynyz) for Anal Cancer (online only)
RELEASE
The FDA has approved oral and injectable formulations of the HIV-1 capsid inhibitor lenacapavir (Yeztugo – Gilead) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adolescents and adults. Lenacapavir is the first drug to be approved for this indication that is given twice-yearly; other drugs approved for this indication are given once daily or once every 2 months. Lenacapavir was approved in 2022 as Sunlenca for use with other antiretroviral drugs to treat multidrug-resistant HIV-1 infection (MDR-HIV) in heavily treatment-experienced adults.1
HIV PrEP — PrEP is generally recommended for HIVnegative persons whose behaviors increase their risk for HIV infection.
Two once-daily oral fixed-dose combinations of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are FDA-approved for HIV-1 PrEP : …